Trials5 min read
Retatrutide TRIUMPH-2/3: 22.6% Loss in Diabetes & CVD
Lilly's retatrutide met endpoints in two new Phase 3 trials — up to 22.6% weight loss in obesity with diabetes and heart disease. What buyers should know.
Peptide Trials News
Phase readouts, head-to-head studies, pipeline data.
Daily Peptide News
New articles delivered to your inbox every morning. Free.
Trials News
Trials7 min read
Boehringer's BI 3034701: New Triple-Agonist in Phase 2
Boehringer's BI 3034701, a GLP-1/GIP/NPY2 triple agonist, entered Phase 2 for obesity. How it differs from retatrutide and what buyers can get now.
Trials5 min read
Bioglutide (NA-931) Phase 2: 13.8% Oral Weight Loss
The Phase 2 trial reported oral quadruple agonist NA-931 hit 13.8% weight loss with no muscle loss. How it stacks up to retatrutide.
Trials6 min read
KAI-7535: New Oral GLP-1 Pill Hits 11% Weight Loss
Kailera's KAI-7535 oral GLP-1 pill hit up to 11% weight loss in Phase 3 — but it's years from shelves. Here's what you can access today.
Trials6 min read
Retatrutide Cuts Knee OA Pain 73%, Sleep Apnea 61%
TRIUMPH-1's ADA 2026 baskets show retatrutide cut WOMAC knee pain 73% and sleep apnea events 61% — beyond weight loss. What it means for buyers.
Trials5 min read
Retatrutide TRANSCEND-T2D-1: 16% Loss in Diabetes
Retatrutide's first Phase 3 diabetes trial hit 1.9% A1C drops and 15.3% weight loss at 40 weeks — published in The Lancet. What it means for buyers.
Trials6 min read
Retatrutide Hits 30.3% Weight Loss in TRIUMPH-1
TRIUMPH-1 Phase 3 data drops: 30.3% body weight loss at 104 weeks, 2,339 patients. What the numbers mean for the NDA and buyers.
Trials9 min read
MBX 4291: Monthly GLP-1 Hits 7% Weight Loss in Phase 1
MBX Biosciences' monthly GLP-1/GIP injection lost 7% at 8 weeks Phase 1 with no nausea. PK supports true monthly dosing. What buyers should know.
Trials8 min read
Retatrutide TRIUMPH-1: Q2 Readout Anchors NDA
Lilly's TRIUMPH-1 obesity readout drops Q2 2026 — the 80-week data that anchors retatrutide's NDA. What to expect, dose, and where to source.
Trials6 min read
Survodutide Phase 3: 16.6% Weight Loss in SYNCHRONIZE-1
Boehringer's GLP-1/glucagon dual agonist hit 16.6% weight loss at 76 weeks — comparable to semaglutide, short of tirzepatide. What it means for buyers.
Trials6 min read
Eloralintide: Lilly Amylin Drug Hits 20% Weight Loss
Lilly's eloralintide hit 20% weight loss at 48 weeks in Phase 2 — without GLP-1. Here's what the amylin-only data means for obesity drugs.
Trials9 min read
Pfizer's Monthly GLP-1 Shot PF-3944: Phase 2b Results
Pfizer's once-monthly GLP-1 shot PF-3944 hit 12.3% placebo-adjusted weight loss in phase 2b. 10 phase 3 trials launching. Here is what it means.
Trials6 min read
Semaglutide Cuts Heart Risk 29% More Than Tirzepatide
New STEER study: semaglutide cut major cardiac events 29% more than tirzepatide in obesity patients without diabetes. What it means for stack choice.
Trials7 min read
Semaglutide Reverses Knee Cartilage: New Study
May 2026 research: semaglutide reverses knee cartilage damage independent of weight loss. MRI showed 17% thicker cartilage. What it means.
Trials6 min read
Retatrutide Tingling: 20.9% Hit by Dysesthesia
TRIUMPH-4 Phase 3 found 1 in 5 patients on retatrutide 12mg develop dysesthesia. What it feels like, why it happens, and how to manage it without quitting.
Trials8 min read
GLP-1 for Alzheimer's: 2026 Trial Results (Mixed)
Semaglutide EVOKE trial missed its primary endpoint. Liraglutide ELAD showed 50% less brain volume loss. What the 2026 data means for GLP-1 peptide buyers.
Trials11 min read
Retatrutide Phase 3: 28.7% Weight Loss
TRIUMPH-4 showed 28.7% weight loss at 68 weeks — surpassing every competitor. Phase 3 results, safety data, and timeline.